Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $136

Benzinga Newsdesk www.benzinga.com Negative 69.0%

Neg 69% Neu 0% Pos 0%

Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $142 to $136.